{"disease":{"id":"ovarian-fallopian-tube-peritoneal-cancer-p53-mutation","name":"ovarian fallopian tube peritoneal cancer p53 mutation"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02272790","title":"Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT04510584","title":"Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University Health Network, Toronto","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}